This Harvard Medical School Continuing Education video examines the key question: Do you know when to use an SGLT2 inhibitor versus a GLP-1 receptor agonist with your patients?
Dr. Lee-Shing Chang, MD, an endocrinologist at Brigham and Women’s Hospital in Boston, Massachusetts, reviews compelling reasons to choose an SGLT2 inhibitor (SGLT2i) vs a GLP-1 receptor agonist (GLP-1 RA). Medical indications, comorbidities and side effects, and the administration of SGLT2i and GLP-1 RA are discussed and compared.
00:00 | Introduction
00:57 | Medical indications for SGLT2i and GLP-1 RA
03:00 | Comorbidities and side effects of SGLT2i and GLP-1 RA
6:07 | Administration differences between SGLT2i and GLP-1 RA
This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content.
References:
Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes. J Am Coll Cardiol. 2020: 76(9): 1117-45. Published 2020 Sep 1. Accessed 22 Jan 2022.
Notice: At this time, the content in this video is not accredited.